Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a next-generation small-molecule multi-target tyrosine kinase inhibitor (TKI) with high selectivity for VEGFR2, PDGFRβ, and FGFR1, with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Chen & Feng 2019). It demonstrates superior anti-angiogenic effects in vitro and in vivo compared to sunitinib and sorafenib [internal]. Anlotinib blocks VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation in a concentration-dependent manner. Pharmacokinetic studies confirm high oral bioavailability (28–77%) and extensive tissue distribution, including tumor and brain. Safety profiles show a high median lethal dose (LD₅₀ 1735.9 mg/kg, oral, 14 days) with low systemic toxicity [APExBIO]. This article details the molecular rationale, evidence benchmarks, practical workflows, and boundaries for research use.

Biological Rationale

Anlotinib hydrochloride was designed to simultaneously inhibit multiple tyrosine kinases implicated in tumor angiogenesis and growth. Tumor vascularization is regulated primarily by VEGF, PDGF, and FGF signaling pathways, which drive endothelial cell proliferation, migration, and capillary network formation. The blockade of VEGFR2, PDGFRβ, and FGFR1 disrupts neovascularization required for tumor expansion and metastasis [internal]. Downstream, these pathways converge on the ERK signaling cascade, modulating cell survival and motility. Anlotinib’s multi-target approach addresses redundancies in angiogenic signaling, reducing the likelihood of compensatory pathway activation seen with single-target inhibitors (Chen & Feng 2019).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule TKI that selectively binds the ATP-binding sites of VEGFR2, PDGFRβ, and FGFR1, inhibiting their phosphorylation activity. Reported IC₅₀ values are 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 under standard biochemical assay conditions (pH 7.4, 25°C, 10 mM Tris buffer) [APExBIO]. This results in potent inhibition of ligand-induced endothelial cell migration and capillary tube formation, measured via EA.hy 926 cell assays. Anlotinib also inhibits additional targets, including c-Kit and MET, and blocks downstream ERK1/2 phosphorylation, further attenuating pro-angiogenic signaling (Chen & Feng 2019). Compared to sunitinib, sorafenib, and nintedanib, anlotinib achieves stronger inhibition of VEGFR2/PDGFRβ/FGFR1 at lower concentrations, as demonstrated in comparative kinase profiling and cell-based functional assays [internal].

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with IC₅₀ = 5.6 ± 1.2 nM (enzyme assay, pH 7.4, 25°C) (APExBIO product data).
• Blocks PDGFRβ activity with IC₅₀ = 8.7 ± 3.4 nM and FGFR1 with IC₅₀ = 11.7 ± 4.1 nM (same conditions) (APExBIO product data).
• Suppresses VEGF/PDGF-BB/FGF-2-induced EA.hy 926 cell migration and tube formation in vitro (10–100 nM, 48 h, serum-free DMEM) (Chen & Feng 2019).
• Demonstrates high oral bioavailability in rats (28–58%) and dogs (41–77%) (pharmacokinetic studies, 5 mg/kg, fasted state) (Chen & Feng 2019).
• High plasma protein binding in humans (93%) and extensive tissue distribution, including lung, liver, kidney, heart, tumor, and brain (LC-MS/MS quantification, 24 h post-dose) (APExBIO).
• Low systemic toxicity: oral LD₅₀ in mice is 1735.9 mg/kg (14-day study), with no significant organ or genetic toxicity (Chen & Feng 2019).
• Clinically, anlotinib demonstrated efficacy in reducing lymph node metastasis in intra-abdominal desmoplastic small round cell tumor (IADSRCT) after chemotherapy failure (Chen & Feng 2019).

Previous articles detailed assay protocols; this article further clarifies molecular selectivity and clinical relevance using updated benchmarks.

Applications, Limits & Misconceptions

Research Applications: Anlotinib hydrochloride is routinely used for:

• In vitro endothelial cell migration and tube formation assays (EA.hy 926, HUVEC models).
• Dissecting VEGFR/PDGFR/FGFR signaling in tumor angiogenesis.
• Comparative studies of TKI selectivity and potency.
• Pharmacokinetic and tissue distribution modeling for anti-cancer agents.

Limits: Anlotinib is not recommended for diagnostic or medical therapeutic use. Its efficacy and toxicity in humans are still under clinical investigation, and usage outside controlled experiments is not validated by APExBIO or regulatory agencies.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Anlotinib is selective for VEGFR2, PDGFRβ, FGFR1, but does not broadly inhibit all tyrosine kinases. Off-target effects are minimal at recommended concentrations.
• Not a direct cytotoxic agent: The compound’s main activity is anti-angiogenic, not direct tumor cell lysis.
• Unsuitable for clinical diagnostics or therapy: Research-use only, per APExBIO and regulatory labeling.
• Not stable above -20°C: Degradation occurs if storage instructions are not followed.
• Does not reverse established vasculature: Best used for prevention or early inhibition of angiogenesis, not regression of mature vessels.

This article extends the systems-biology focus in this review by providing quantitative benchmarks and practical assay guidance for new users.

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688, APExBIO) is provided as a dry powder, recommended for storage at -20°C. For cell-based assays, dissolve in DMSO to prepare a 10 mM stock, and dilute to working concentrations (5–100 nM) in serum-free DMEM. Typical endothelial cell migration assays use EA.hy 926 or HUVEC cells, seeded at 1–2 x 10⁴ cells/well, treated for 24–48 h. Quantify migration via wound-healing or transwell assays; tube formation by Matrigel-based imaging after 6–16 h incubation. For kinase activity, use a luminescence or radiometric endpoint as described in published protocols [internal]. For in vivo studies, oral gavage at 1–10 mg/kg in appropriate animal models is common, monitoring for toxicity and bioavailability. Cytochrome P450 metabolism (primarily CYP3A) should be considered in drug–drug interaction studies, especially in multi-compound screens.

This article updates prior mechanistic discussions by systematically mapping experimental parameters and highlighting storage and handling limitations.

Researchers should always source from validated suppliers such as APExBIO to ensure lot traceability and consistency.

Conclusion & Outlook

Anlotinib hydrochloride offers a well-validated tool for dissecting tumor angiogenesis and tyrosine kinase signaling pathways in preclinical models. Its multi-target selectivity, high bioavailability, and favorable safety profile make it suitable for advanced endothelial and cancer research workflows. While promising results in rare tumor types (e.g., IADSRCT) are emerging (Chen & Feng 2019), further clinical validation is required. The product’s robust data and consistent performance position it as a preferred research reagent in anti-angiogenic studies.